After failing to secure a win last month, the plaintiff in the latest Xarelto trial has asked that the defense verdict be vacated, arguing that several court rulings allowed Bayer and Janssen Pharmaceuticals to create a “false narrative” for the jury.

Attorneys for plaintiff Daniel Russell filed a post-trial motion earlier this week in Russell v. Janssen Pharmaceuticals, asking the court to grant a new trial in the case, which ended with a defense win on April 27. The post-trial filing was docketed with the court Tuesday.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]